Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Team with CapitalBio on MDx Applications

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics today said that it has signed a memorandum of understanding to collaborate with China's CapitalBio on developing molecular diagnostics applications and technologies to serve unmet needs of researchers worldwide.

Specifically, the alliance aims to further develop microarray technologies and complementary products for molecular diagnostics applications. The initial focus will be on enhancing and automating the Roche NimbleGen microarray workflow for preventive and personalized diagnostics, said Roche.

The firms also plan to cooperate on education efforts on the benefits and use of molecular diagnostics that exploit technologies such as microarrays and Roche 454 Life Sciences' next-generation sequencing products in China and international markets. According to Fatt-Heng Wong, GM of Roche Diagnostics Shanghai, the firms also plan to cooperate in marketing products in the greater China and international markets.

Financial and other terms of the alliance were not disclosed.

CapitalBio already serves as certified service provider of NimbleGen products. The firm operates a medical testing lab in Chengdu and a microarray genomics service facility at its headquarters in Beijing.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.